Aurobindo Pharma: Nod for niche drugs, strong pipeline to push earnings

Analysts at Elara Capital say Ertapenem approval gives comfort to Aurobindo's ability to grow its US business in FY19, despite the high base

Aurobindo Pharma has been in the news and for good reasons. The most recent has been the receipt of an approval for a complex injectable product launch in the US. The approval of anti-bacterial injection, Ertapenem, provides a significant opportunity with limited competition.
 
The approval has also boosted confidence in the company’s injectables portfolio and its US business. Concerns over pricing pressure in the US and FDA inspections at its various manufacturing units had  pushed down its stock to 52-week lows in early June. With FDA clearance to its Unit-IV (manufactures injectables) and product approval from its penem injectables